Evidence map›Paper›PMID 36713354›Full record

ArticleHemaSphere2023

Baseline

David Morland, Lukshe Kanagaratnam, Fabrice Hubelé, Elise Toussaint, Sylvain Choquet, Aurélie Kas, Pierre-Ambroise Caquot, Corinne Haioun, Emmanuel Itti, Stéphane Leprêtre and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 3 countries.

David MorlandMédecine Nucléaire, Institut Godinot, Reims, France.
Lukshe KanagaratnamUnité d'Aide Méthodologique, Pôle Recherche et Santé Publique, CHU de Reims, Reims, France.
Fabrice HubeléMédecine Nucléaire, CHU de Strasbourg, ICANS, Strasbourg, France.
Elise ToussaintHématologie, CHU de Strasbourg, ICANS, Strasbourg, France.
Sylvain ChoquetHématologie, CHU Pitié-Salpêtrière Charles Foix, Sorbonne Université, AP-HP, Paris, France.
Aurélie KasMédecine Nucléaire, CHU Pitié-Salpêtrière Charles Foix, Sorbonne Université, AP-HP, Paris, France.
Pierre-Ambroise CaquotMédecine Nucléaire, Institut Godinot, Reims, France.
Corinne HaiounHématologie, CHU Henri Mondor, AP-HP, Créteil, France.
Emmanuel IttiMédecine Nucléaire, CHU Henri Mondor, AP-HP, Créteil, France.
Stéphane LeprêtreInserm U1245 et Département d'Hématologie, Centre Henri Becquerel et Normandie Univ, UNIROUEN, Rouen, France.
Pierre DecazesMédecine Nucléaire, Centre Henri Becquerel, Rouen, France.
Fontanet BijouHématologie, Institut Bergonié, Bordeaux, France.
Paul SchwartzMédecine Nucléaire, Institut Bergonié, Bordeaux, France.
Caroline JacquetHématologie, CHU de Nancy, France.
Adrien ChauchetHématologie, CHU de Besançon, France.
Julien MatuszakMédecine Nucléaire, CHU de Besançon, France.
Nassim KamarNéphrologie et transplantation d'organes, CHU Rangueil, Toulouse, France.
Pierre PayouxMédecine Nucléaire, CHU de Toulouse, France.
Eric DurotHématologie clinique, CHU de Reims, France.
Centre Hospitalier Universitaire de Reims · FRSorbonne Université · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire Henri-Mondor · FRInstitut Bergonié · FRInstitut de Cancérologie Strasbourg · FRAgostino Gemelli University Polyclinic · ITCentre Henri BecquerelCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Toulouse · FRHôpital Rangueil · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a rare complication of immunosuppression. Sequential treatment is commonly proposed, combining induction with rituximab (R-induction) followed by either continuation of treatment or addition of chemotherapy depending on response. Response to R-induction, often assessed by CT scan, is a major predictor of overall survival (OS). The aim of the study was to analyze predictive factors of R-induction response, including total metabolic tumor volume (TMTV), and investigate the role of

Identifiers

PMID36713354
PMCPMC9875954
OpenAlexW4318542833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.